Welcome to our dedicated page for Betterlife Pharma news (Ticker: BETRF), a resource for investors and traders seeking the latest updates and insights on Betterlife Pharma stock.
BetterLife Pharma Inc. develops BETR-001, a proprietary non-hallucinogenic derivative of LSD and neuroplastogen, for psychiatric and neurological disorders. News about BETRF commonly covers scientific updates on BETR-001’s mechanism of action and neuroplastogenic activity, intellectual property and regulatory-preparation disclosures, and disease areas such as traumatic brain injury, post-traumatic stress disorder, cluster headache, depression and anxiety.
Company updates also include strategic partnering and conference participation, development alternatives for its viral-infection therapeutic candidate, debt settlements and warrant exercises, board and advisory appointments, and public-company disclosure matters in Canada and the U.S. OTC market.
BetterLife Pharma (CSE: BETR, OTCQB: BETRF) appointed Charles Duncan, PhD as Director and Chair of the Audit Committee as of August 31, 2026. Duncan is a longtime biotechnology strategist and former top-ranked Wall Street biotechnology analyst with nearly 30 years of experience in capital markets, corporate strategy and life sciences.
According to BetterLife, Duncan currently serves as Managing Director, Head of Biotech Strategy & Development at Gilmartin Group and sits on the Board of Vanda Pharmaceuticals. He has covered over 175 biotechnology companies and evaluated more than 200 investment banking transactions, with sector expertise in neurology, psychiatry and oncology.
In connection with his appointment, BetterLife agreed to grant Duncan stock options to purchase 500,000 common shares, vesting quarterly over 24 months with a 10‑year term, plus 125,000 additional options vesting over 3 months, also with a 10‑year term. Exercise prices will follow Canadian Securities Exchange policies.
BetterLife Pharma (OTCQB: BETRF) appointed neurologist and headache specialist Mahan Chehrenama, DO, as Chief Medical Officer. She will lead clinical development of BETR-001, BetterLife’s non-hallucinogenic neuroplastogen, which is advancing toward an IND application for migraine and other headache disorders, anticipated in the first quarter of 2027.
Dr. Chehrenama brings nearly a decade of senior biopharma development experience and over two decades of clinical practice, including leadership roles at Manistee Therapeutics, Amgen, Revance Therapeutics, and Avanir Pharmaceuticals. BetterLife granted her options to purchase 500,000 common shares at $0.285, vesting quarterly over 24 months, with a 10‑year term.
BetterLife Pharma (OTCQB: BETRF) is prioritizing its lead clinical-stage asset BETR-001, a fully non-hallucinogenic, oral, non-scheduled 5-HT2A neuroplastogen, for migraine and primary headache disorders as lead indications. The program leverages an FDA-precedented serotonergic mechanism used in multiple approved migraine drugs and a human pilot signal of efficacy for racemic 2-bromo-LSD in cluster headache.
According to BetterLife, BETR-001 is covered by a U.S. composition-of-matter patent to 2042, has completed an FDA pre-IND meeting, initiated its final IND-enabling toxicity study, substantially completed GMP scale-up manufacturing, and is expected to have an IND filing in 1Q 2027. Psychiatric and other neurologic indications remain future optional opportunities.
BetterLife Pharma (OTCQB: BETRF) appointed biopharmaceutical executive John W. LaRocca to its Board of Directors and Audit Committee. LaRocca has three decades of public-company legal, compliance, M&A, and governance experience, including roles at multiple Nasdaq-listed firms.
He will receive options for 500,000 shares at $0.19. BetterLife also raised $40,000 from the exercise of 350,000 warrants to fund BETR-001 development and working capital.
BetterLife (OTCQB: BETRF) has engaged Nucro-Technics to conduct the last IND-enabling GLP toxicology study of its lead candidate BETR-001. BETR-001, a non-hallucinogenic 2-bromo-LSD derivative, is being developed for migraine and cluster headache. The FDA IND filing is projected for Q1 2027, supporting a planned Phase 1 program.
BetterLife (CSE: BETR, OTCQB: BETRF) signed an agreement with Syner-G BioPharma to oversee GMP manufacturing of its investigational compound BETR-001 for a planned IND and Phase 1 program.
BETR-001 targets chronic cluster headache and chronic migraine, with IND filing and Phase 1 start projected for Q1 2027. BetterLife also engaged GTM Studios for two months at $4,000 per month to produce marketing materials, and clarified the exercise price of 3,250,000 stock options granted June 15, 2026 is $0.07.
BetterLife Pharma (OTCQB: BETRF) closed a CAD $2,000,000 convertible debenture to fund remaining FDA IND-enabling work for lead compound BETR-001, focused on neurological pain, including cluster headache and migraine.
The debenture bears 10% interest, matures June 1, 2027, and is convertible at CAD $0.06 per unit with attached warrants.
BetterLife Pharma (OTCQB: BETRF) appointed Doug Drysdale, formerly CEO of Cybin, as Executive Chairman and Director. Drysdale previously led Cybin from molecule inception to Phase 3 trials in three years and is recognized for advocating innovation in mental healthcare.
BetterLife granted him stock options for 3,500,000 shares at an exercise price of $0.065, vesting monthly over 24 months with a 10-year term.
BetterLife Pharma (OTCQB: BETRF) will participate in the YAFO Capital Access Asia 2025 Partnering Forum in San Francisco during JPM Week, with the YAFO event on January 11, 2026.
CEO Dr. Ahmad Doroudian will attend additional meetings: H7 Life Science Investment Forum & China Night Reception on January 12, 2026, WuXi Global Forum on January 13, 2026, and DARPA & Ferocity Capital Biodefence Summit on January 13, 2026. He is available for one-on-one meetings with investors and partners; scheduling requests are directed to the CEO's contact.
BetterLife is developing BETR-001, a patented stereoisomer of 2-bromo-LSD described as a non-hallucinogenic neuroplastogen being studied for traumatic brain injury, PTSD, and cluster headache; a small prior study (Karst et al, Cephalgia 2010) reported reduced cluster headache frequency.
BetterLife Pharma (OTCQB: BETRF) announced an engagement agreement dated December 11, 2025 to retain Shanghai-based YAFO Capital as its exclusive advisor for seeking strategic partnerships for development of BETR-001 in the Greater China region (mainland China, Hong Kong, Taiwan and Macau).
The company said it will retain YAFO on a non-exclusive basis for territories outside Greater China. BETR-001 is described as a patented, non-hallucinogenic stereoisomer of 2-bromo-LSD being developed for traumatic brain injury, PTSD and cluster headache.